Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease. Belite Bio, Inc has dosed the first patient at the Tokyo Medical Center in the ...
According to the company, the axitinib injectable suspension achieved all primary and secondary outcomes and maintained stable visual acuity and anatomical control over 9 months. There were no ocular ...
Everads suprachoroidal delivery technology is designed to enable safe and effective in-office delivery of therapies to the choroidal and retinal tissues via the suprachoroidal space. Everads Therapy ...